ライフサイエンスコーパス: severe sepsis

1 r less than two SIRS criteria (SIRS-negative severe sepsis).

2 eated in an external acute care hospital for severe sepsis.

3 an intervention that may improve outcomes in severe sepsis.

4 chers recruited a total of 632 patients with severe sepsis.

5 h, quality improvement, and health policy in severe sepsis.

6 dition to standard of care, in patients with severe sepsis.

7 care for the patient after their episode of severe sepsis.

8 ty in critically ill patients with trauma or severe sepsis.

9 sis; impact on caregivers; and support after severe sepsis.

10 ired severe sepsis and healthcare-associated severe sepsis.

11 y to trials of acute respiratory failure and severe sepsis.

12 should be aware of this important sequela of severe sepsis.

13 of ICU and hospital stay increased with more severe sepsis.

14 are not being measured in many patients with severe sepsis.

15 sepsis, and 34,829 (11.3%) hospital-acquired severe sepsis.

16 failure to measure lactates in patients with severe sepsis.

17 lanced fluids for resuscitation in pediatric severe sepsis.

18 he plasma cortisol profiles in patients with severe sepsis.

19 sepsis and 13,278 (12.1%) had SIRS-negative severe sepsis.

20 among mechanically ventilated patients with severe sepsis.

21 udy was to explore myocardial dysfunction in severe sepsis.

22 PICU patients diagnosed with severe sepsis.

23 gh dose in older adults, but not during more severe sepsis.

24 % CI, 3.8-10.3) vs 3.5 (95% CI, 2.2-5.5) for severe sepsis.

25 al mortality among transferred patients with severe sepsis.

26 bacteria (GNBs) are common pathogens causing severe sepsis.

27 n-hospital mortality than did either SIRS or severe sepsis.

28 Vitamin D deficiency is common in severe sepsis.

29 antibiotics in critically ill patients with severe sepsis.

30 quential Organ Failure Assessment score, and severe sepsis.

31 severe sepsis (25.9%), and hospital-acquired severe sepsis (11.3%) cases.

32 severe sepsis (62.8%), healthcare-associated severe sepsis (25.9%), and hospital-acquired severe seps

33 son of Eritoran and placebo in patients with Severe Sepsis, 580 patients had a quality of life measur

34 8.3 per 1,000 person-years) and 1,151 first severe sepsis (6.2 per 1,000 person-years) events.

35 he estimated 5,257,907 hospitalizations with severe sepsis, 6.1% had acute kidney injury requiring di

36 hospitalizations included community-acquired severe sepsis (62.8%), healthcare-associated severe seps

37 including 193,081 (62.8%) community-acquired severe sepsis, 79,581 (25.9%) healthcare-associated seve

38 with vs those without SOT (5.5% vs 9.4% for severe sepsis; 8.7% vs 12.7% for sepsis).

39 odification diagnosis of septicemia (038.x), severe sepsis (995.92), or septic shock (785.52), as wel

40 ociated severe sepsis, and hospital-acquired severe sepsis, adjusted hospital mortality, length of ho

41 In patients with severe sepsis, admission secretoneurin levels (logarithm

42 We identified 56,997 patients with severe sepsis admitted to 124 U.S. academic hospitals du

43 dent predictor of mortality in patients with severe sepsis, although its influence on mortality decli

44 tem failure to identify hospitalizations for severe sepsis among patients aged 18-64 between 2000 and

45 In severe sepsis, an extracorporeal treatment which modulat

46 (95% confidence interval [CI], .79-.87) for severe sepsis and 0.78 (95% CI, .73-.84) for sepsis.

47 e, 96,385 patients (87.9%) had SIRS-positive severe sepsis and 13,278 (12.1%) had SIRS-negative sever

48 is a frequent complication in patients with severe sepsis and can worsen the prognosis.

49 ammatory responses to LPS and developed more severe sepsis and colitis, with greater mortality.

50 utilization than both healthcare-associated severe sepsis and community-acquired severe sepsis, with

51 better understood, the incidence of maternal severe sepsis and deaths continues to increase.

52 asma F2-isoprostanes, in adult patients with severe sepsis and detectable plasma cell-free hemoglobin

53 In adults with severe sepsis and detectable plasma cell-free hemoglobin

54 splant recipients are more likely to develop severe sepsis and die following a severe sepsis episode

55 Hospital-acquired severe sepsis and healthcare-associated severe sepsis ex

56 resource utilization than community-acquired severe sepsis and healthcare-associated severe sepsis.

57 ional cohort of critically ill children with severe sepsis and high mortality rates, septic acute kid

58 eria meningitidis (MenB) is a major cause of severe sepsis and invasive meningococcal disease, which

59 n outpatient setting, and (4) infection with severe sepsis and managed in an inpatient setting with i

60 th reduced 28-day mortality in patients with severe sepsis and may even be harmful.

61 son of Eritoran and placebo in patients with Severe Sepsis and PROWESS-SHOCK, respectively).

62 son of Eritoran and placebo in patients with Severe Sepsis and PROWESS-SHOCK, the average age of pati

63 Among hospitalizations for severe sepsis and sepsis, in-hospital mortality was lowe

64 We searched for terms related to severe sepsis and septic shock and terms related to poly

65 Severe sepsis and septic shock are life-threatening cond

66 Sepsis, severe sepsis and septic shock are the main cause of mor

67 pact of a quality improvement initiative for severe sepsis and septic shock focused on the resuscitat

68 nfections remain the most important cause of severe sepsis and septic shock following splenectomy.

69 atment may reduce mortality in patients with severe sepsis and septic shock in specific disease sever

70 Consecutive sample of all severe sepsis and septic shock patients (defined: infect

71 ater than or equal to one bundle element for severe sepsis and septic shock patients.

72 Patients with severe sepsis and septic shock treated between 2009 and

73 The incidence of severe sepsis and septic shock was 9.7%.

74 esis of sepsis and its spectrum of diseases (severe sepsis and septic shock), which are leading cause

75 sion treatment on mortality in patients with severe sepsis and septic shock.

76 age or within 1 hour of shock recognition in severe sepsis and septic shock.

77 t the lactate concentration in patients with severe sepsis and septic shock.

78 and may decrease mortality in patients with severe sepsis and septic shock.

79 adult medical and surgical ICU patients with severe sepsis and septic shock.

80 f antibiotic administration and mortality in severe sepsis and septic shock.

81 ate antimicrobial treatment in patients with severe sepsis and septic shock.

82 n B hemoperfusion treatment in patients with severe sepsis and septic shock.

83 th normal blood lactate concentration during severe sepsis and septic shock: survival (p = 0.03) and

84 s greater than or equal to 18 years old with severe sepsis and/or septic shock and antimicrobial admi

85 Patients with severe sepsis and/or septic shock.

86 epsis, 0.4% (95% CI, 0.1-0.8%; P = 0.02) for severe sepsis, and 1.8% (95% CI, 0.8-3.0%; P = 0.001) fo

87 ere admitted with sepsis, 1,071 (62.5%) with severe sepsis, and 21 (1.2%) with septic shock.

88 sepsis, 79,581 (25.9%) healthcare-associated severe sepsis, and 34,829 (11.3%) hospital-acquired seve

89 s at risk (95% CI, 430-485) in patients with severe sepsis, and 9/100,000 person-years at risk (95% C

90 cquired severe sepsis, healthcare-associated severe sepsis, and hospital-acquired severe sepsis hospi

91 cquired severe sepsis, healthcare-associated severe sepsis, and hospital-acquired severe sepsis, adju

92 40% (95% CI, 36-44) in patients with sepsis, severe sepsis, and septic shock, respectively.

93 f sepsis (3.5%, 9.9%, and 28.6%, for sepsis, severe sepsis, and septic shock, respectively; p < 0.05)

94 emic inflammatory response syndrome, sepsis, severe sepsis, and septic shock.

95 d safety of heparin in patients with sepsis, severe sepsis, and septic shock.

96 To determine whether sepsis and severe sepsis are associated with vitamin D deficiency a

97 medical emergency department with sepsis and severe sepsis are more frequent than previously reported

98 onal clinical trials targeting children with severe sepsis are warranted.

99 frequent medical condition that can trigger severe sepsis as a life-threatening complication.

100 We defined community-acquired severe sepsis as all other severe sepsis patients with a

101 Patients younger than 18 years of age with severe sepsis as defined by consensus criteria were incl

102 We defined healthcare-associated severe sepsis as severe sepsis hospitalizations with an

103 We defined hospital-acquired severe sepsis as severe sepsis patients where the docume

104 ssion rates following hospital admission for severe sepsis as well as institutional variations in rea

105 had blood cultures ordered and patients with severe sepsis, as defined by concomitant International C

106 annual incidence of septicemia, sepsis, and severe sepsis at 2 academic hospitals from 2003 to 2012

107 0 days, 66.9% had an infection and 40.3% had severe sepsis at readmission.

108 Compared with controls, in severe sepsis, baseline plasma total cortisol was elevat

109 tem failure to identify hospitalizations for severe sepsis between 2000 and 2008.

110 muscle fiber atrophy develops in response to severe sepsis, but it is unclear as to how the proteolyt

111 variation between hospitals in their care of severe sepsis, but little information on whether this va

112 awareness of diagnosis and understanding of severe sepsis by patients and caregivers and difficultie

113 hether hospital and regional organization of severe sepsis care is associated with meaningful differe

114 ssociations bolster arguments to regionalize severe sepsis care, an approach that may necessitate int

115 l, there was an inverse relationship between severe sepsis case volume and inpatient mortality.

116 iations between quintiles of annual hospital severe sepsis case volume for the receiving hospital and

117 e to a care facility, higher hospital annual severe sepsis case volume, and higher hospital sepsis mo

118 predictors of failure to measure lactates in severe sepsis cases in 2013.

119 is and 270 (95% CI, 176-412; tau = 0.60) for severe sepsis cases per 100,000 person-years.

120 CI, 98-226; tau = 0.99) for hospital-treated severe sepsis cases per 100,000 person-years.

121 ates of 31.5 million sepsis and 19.4 million severe sepsis cases, with potentially 5.3 million deaths

122 patients accounted for 13.2% of hospitalized severe sepsis cases.

123 Patients in one of three severe sepsis cohorts: 1) explicitly coded (n = 108,448)

124 e was significantly greater in patients with severe sepsis compared with all other diagnoses (OR, 1.0

125 HIV-infected patients with severe sepsis continue to suffer worse outcomes compared

126 Thirty-day mortality after severe sepsis declined from 18.3% in 2008 to 14.7% in 20

127 Total function limitations following severe sepsis did not differ by body mass index category

128 son of Eritoran and placebo in patients with Severe Sepsis died or reported persistent problems at 1

129 hcare system, with one in 15 and one in five severe sepsis discharges readmitted within 7 and 30 days

130 Among 216,328 eligible severe sepsis discharges, there were 14,932 readmissions

131 poietic stem cell transplant recipients with severe sepsis during engraftment and subsequent admissio

132 tal mortality was 17% for sepsis and 26% for severe sepsis during this period.

133 Of 1,095 patients with severe sepsis enrolled, 165 (15%) were positive for HIV,

134 to develop severe sepsis and die following a severe sepsis episode than nontransplant patients.

135 psis Risk Score predicting future sepsis and severe sepsis events among community-dwelling adults.

136 need for two or more SIRS criteria to define severe sepsis excluded one in eight otherwise similar pa

137 ired severe sepsis and healthcare-associated severe sepsis exhibited higher in-hospital mortality tha

138 itative analysis: awareness and knowledge of severe sepsis; experience of hospitalization, ongoing im

139 es, Ninth Revision (ICD-9) codes to identify severe sepsis, explicitly coded sepsis, and SOT (kidney,

140 study of adults (>/=20 yr) hospitalized with severe sepsis from 2000 to 2009 in the United States usi

141 s have not differentiated community-acquired severe sepsis from healthcare-associated severe sepsis o

142 provided good-to-excellent discrimination of severe sepsis from severe SIRS (0.742-0.917 AUC of ROC c

143 The study extends what was understood about severe sepsis from the patients' and caregivers' perspec

144 Sixty-one patients with sepsis and severe sepsis from two large U.K. hospitals and 20 healt

145 Survivors of severe sepsis had 1.1-fold higher risk compared with mat

146 Hospital-acquired severe sepsis had greater resource utilization than both

147 Patients with severe sepsis had significantly lower concentrations of

148 y injury requiring dialysis in patients with severe sepsis has also declined.

149 y injury requiring dialysis in patients with severe sepsis has increased over time; conversely, assoc

150 Prevalence of community-acquired severe sepsis, healthcare-associated severe sepsis, and

151 t to compare and contrast community-acquired severe sepsis, healthcare-associated severe sepsis, and

152 n-hospital mortality than community-acquired severe sepsis (hospital acquired [19.2%] vs healthcare a

153 We examined whether higher risk is due to severe sepsis hospitalization or poor prehospitalization

154 known to result in dysbiosis and subsequent severe sepsis hospitalization that is not present for re

155 There were 903 816 severe sepsis hospitalizations (39 618 [4.4%] with SOT)

156 Severe sepsis hospitalizations and organism-specific cau

157 ociated severe sepsis, and hospital-acquired severe sepsis hospitalizations in a national hospital sa

158 In this series, severe sepsis hospitalizations included community-acquir

159 The data for 5,033,257 severe sepsis hospitalizations were examined and reveale

160 fined healthcare-associated severe sepsis as severe sepsis hospitalizations with an infection present

161 ssociated severe sepsis or hospital-acquired severe sepsis hospitalizations.

162 rience of hospitalization, ongoing impact of severe sepsis; impact on caregivers; and support after s

163 uspected sepsis in only 65% of patients with severe sepsis in 2013.

164 examine factors associated with mortality of severe sepsis in hematopoietic stem cell transplant reci

165 The frequency of severe sepsis in hematopoietic stem cell transplant reci

166 The management of severe sepsis in obstetrics is multidisciplinary.

167 he qSOFA performed better than both SIRS and severe sepsis in predicting in-hospital mortality, with

168 I]) were associated with increasing risk for severe sepsis in the 90 days after hospital discharge.

169 The underlying mechanisms of severe sepsis in the development of posttraumatic stress

170 d or older and had experienced an episode of severe sepsis in the previous 12 months were recruited b

171 Reports of outcomes of severe sepsis in this population are limited to data fro

172 hospital discharges, there were 307,491 with severe sepsis, including 193,081 (62.8%) community-acqui

173 Severe sepsis induced marked apoptosis in the thymus, sp

174 ous infusion in critically ill patients with severe sepsis is associated with decreased hospital mort

175 Severe sepsis is increasing in incidence and has a high

176 ging from mild or asymptomatic infections to severe sepsis-like presentations or meningoencephalitis.

177 Infants presented with a severe sepsis-like syndrome with a high rate of ICU admi

178 We not only confirmed an overall decline in severe sepsis mortality from 1999 to 2008 but also ident

179 ternally validate, and externally validate a severe sepsis mortality prediction model and associated

180 This study explored organism-specific severe sepsis mortality trends from 1999 to 2008 in a la

181 cent studies have reported decreased overall severe sepsis mortality, but associations with organism

182 y unreported variations in organism-specific severe sepsis mortality.

183 Conclusions and Relevance: Among adults with severe sepsis not in septic shock, use of hydrocortisone

184 re the effects of dopamine or epinephrine in severe sepsis on 28-day mortality; secondary outcomes we

185 nical trial who lived independently prior to severe sepsis, one third had died and of those who survi

186 d mortality among patients hospitalized with severe sepsis or explicitly coded sepsis in 2012-2014.

187 red severe sepsis from healthcare-associated severe sepsis or hospital-acquired severe sepsis hospita

188 Among patients hospitalized for severe sepsis or sepsis, those with SOT had lower inpati

189 ardiac troponin T are frequently elevated in severe sepsis or septic shock and have relevant prognost

190 All adults treated with severe sepsis or septic shock between 2005 and 2014, usi

191 We enrolled 3,663 patients with severe sepsis or septic shock during three 4-month perio

192 Consecutive patients presenting with severe sepsis or septic shock from 2011 to 2013.

193 pectively enrolled consecutive patients with severe sepsis or septic shock in 2 intensive care units

194 as a qualifier for future clinical trials in severe sepsis or septic shock in patient populations who

195 6 hours of presentation in the management of severe sepsis or septic shock in this subset analysis of

196 Critically ill patients with severe sepsis or septic shock may need relatively high c

197 ion bundle, measuring serum lactate in adult severe sepsis or septic shock patients and its interacti

198 Among patients with severe sepsis or septic shock receiving antimicrobials i

199 and shorter hospital stays in patients with severe sepsis or septic shock subsequently admitted to t

200 Two hundred sixty patients with severe sepsis or septic shock were included.

201 ours of hospital arrival with a diagnosis of severe sepsis or septic shock were included.

202 ICU adult patients with severe sepsis or septic shock who had Cl measured on ICU

203 tional, cohort study involving patients with severe sepsis or septic shock who received colistin was

204 Consecutive patients meeting criteria for severe sepsis or septic shock who were admitted to the I

205 Fifty-two patients with severe sepsis or septic shock with asplenia and 52 witho

206 25-hydroxyvitamin D levels in patients with severe sepsis or septic shock.

207 trospectively identified adult patients with severe sepsis or septic shock.

208 presentation for all patients with suspected severe sepsis or septic shock.

209 th Revision, Clinical Modification codes for severe sepsis or septic shock.

210 t between 2009 and 2015 for fluid-refractory severe sepsis or septic shock.

211 ferol (n = 10), within 24 hours of new-onset severe sepsis or septic shock.

212 in severely obese and nonobese patients with severe sepsis or septic shock.

213 ing two or more SIRS criteria (SIRS-positive severe sepsis) or less than two SIRS criteria (SIRS-nega

214 dmitted to intensive care units with sepsis, severe sepsis, or septic shock (as defined by the Intern

215 th Enterobacteriaceae bacteremia and sepsis, severe sepsis, or septic shock.

216 a, sepsis, organ dysfunction plus infection, severe sepsis, or septic shock.

217 s 0.65 (95% CI, 0.59-0.70) for both SIRS and severe sepsis (P < .001; incremental AUROC, 0.15; 95% CI

218 oad-spectrum antimicrobial administration in severe sepsis patients admitted through the emergency de

219 xclusive use of balanced fluids in pediatric severe sepsis patients for the first 72 hours of resusci

220 Hospitalized severe sepsis patients identified from National Health I

221 e defined hospital-acquired severe sepsis as severe sepsis patients where the documented infection wa

222 ommunity-acquired severe sepsis as all other severe sepsis patients with an infection present at admi

223 We identified 3,929 severe sepsis patients, with overall mortality 12.8%.

224 In severe sepsis, plasma-free cortisol increase is 10-fold

225 Outcomes were severe sepsis point prevalence, therapies used, new or p

226 Severe sepsis poses a major burden on the U.S. healthcar

227 Greatest increases were seen for severe sepsis present on admission (3.8-fold increase).

228 Of 6,925 patients screened, 569 had severe sepsis (prevalence, 8.2%; 95% confidence interval

229 ther hydrocortisone therapy in patients with severe sepsis prevents the development of septic shock.

230 Severe sepsis readmission places a substantial burden on

231 Children with pediatric severe sepsis receiving balanced fluids for resuscitatio

232 Readmissions after severe sepsis remain understudied and could possibly sig

233 Pediatric severe sepsis remains a burdensome public health problem

234 The consensus definition of severe sepsis requires suspected or proven infection, or

235 Severe sepsis requires timely management and has high mo

236 lock size stratified by site and presence of severe sepsis requiring vasopressors to receive either r

237 Sepsis Risk Score predict 10-year sepsis and severe sepsis risk among community-dwelling adults and m

238 The Sepsis Risk Score and Severe Sepsis Risk Score exhibited good discrimination (

239 rs in the best derived Sepsis Risk Score and Severe Sepsis Risk Score included chronic lung disease,

240 The Sepsis Risk Score and Severe Sepsis Risk Score predict 10-year sepsis and seve

241 nternally validate a Sepsis Risk Score and a Severe Sepsis Risk Score predicting future sepsis and se

242 Severe Sepsis Risk Score risk categories were very low (

243 Organ Failure Assessment score of 0.86, and Severe Sepsis Score of 0.82.

244 Sequential Organ Failure Assessment, and the Severe Sepsis Score were entered into a database.

245 erfusion, a key element in the management of severe sepsis, septic shock and in sports performance ev

246 ervices adopted the Early Management Bundle, Severe Sepsis/Septic Shock (SEP-1) performance measure t

247 D) team dedicated to the early management of severe sepsis/septic shock (SS/SS) in Emergency Departme

248 obtained from 74 patients within 12 hours of severe sepsis/septic shock (SS/SS), and at set intervals

249 Changes of metabolites between sepsis and severe sepsis/septic shock also varied according to the

250 inear trend) to a 706% increase for explicit severe sepsis/septic shock codes (P = .001).

251 riage and 2) administration within 1 hour of severe sepsis/septic shock recognition.

252 evaluable for antibiotic administration from severe sepsis/septic shock recognition.

253 polyneuropathy/critical illness myopathy and severe sepsis/septic shock studies.

254 th Revision, Clinical Modification codes for severe sepsis/septic shock, 2) Martin approach, and 3) A

255 Within severe sepsis/septic shock, patients with bloodstream in

256 thy/critical illness myopathy and those with severe sepsis/septic shock.

257 and without asplenia and community-acquired severe sepsis/septic shock.

258 th community-acquired pneumonia in sepsis or severe sepsis/septic shock.

259 received antibiotics more than 1 hour after severe sepsis/shock recognition (< 1 hr reference) had a

260 an 5 hours in antibiotic administration from severe sepsis/shock recognition.

261 clinical trials exploring new treatments in severe sepsis should incorporate individual organism tre

262 used data from an international prospective severe sepsis study to elucidate functional outcomes of

263 l analysis of the Antibiotic Intervention in Severe Sepsis study, a Spanish national multicenter educ

264 vitro in milder infective events, but not in severe sepsis, supporting their potential utility as an

265 ciated cost and mortality of readmissions in severe sepsis survivors.

266 cohort of 40 children with clinically overt severe sepsis syndrome and 30 children immediately postc

267 The clinically overt severe sepsis syndrome children had confirmed or highly

268 rdiopulmonary bypass versus clinically overt severe sepsis syndrome descriptors included the followin

269 tcardiopulmonary bypass and clinically overt severe sepsis syndrome groups in children.

270 for 35 of 40 (87.5%) of the clinically overt severe sepsis syndrome patients and 29 of 30 (96.7%) of

271 tcardiopulmonary bypass and clinically overt severe sepsis syndrome patients by receiver operating ch

272 In critically ill patients with severe sepsis, there was no difference in outcomes betwe

273 In severe sepsis, there were no differences in plasma total

274 cripts are highly expressed in patients with severe sepsis; thus, suggesting that these pathways are

275 is associated with increased progression of severe sepsis to septic shock and increased mortality.

276 imicrobial is associated with progression of severe sepsis to septic shock.

277 odel that sepsis follows a continuum through severe sepsis to shock, and inadequate specificity and s

278 (weighted national estimate of 717,732) with severe sepsis transferred from another acute care hospit

279 ume-outcome associations among patients with severe sepsis transferred from another hospital.

280 ligible articles, we included 36 multicenter severe sepsis trials, with a total of 14,418 participant

281 The incidence rate ratio (IRR) of severe sepsis was 3.3-fold greater during the 90 days af

282 The leading cause of severe sepsis was 51.5% Gram-negative bacteria, followed

283 Hospital-acquired severe sepsis was associated with both higher mortality

284 The task force concluded the term severe sepsis was redundant.

285 eta-analysis of critically ill patients with severe sepsis, we aimed to compare clinical outcomes of

286 ed probabilities of subsequent admission for severe sepsis were 4.1% (95% confidence interval [CI], 3

287 Three cohorts of patients with severe sepsis were created: 1) International Classificat

288 poietic stem cell transplant recipients with severe sepsis were identified.

289 n the intestine of animals with moderate and severe sepsis were significantly lower than that of sham

290 any, and it included 380 adult patients with severe sepsis who were not in septic shock.

291 ted to one of the participating centers with severe sepsis who were receiving antimicrobial therapy a

292 tal mortality was lowest among patients with severe sepsis who were transferred to high-volume hospit

293 gnostic biomarker for risk of progression to severe sepsis with circulatory failure in a multicenter

294 andomized into controls, mild, moderate, and severe sepsis with equal number of animals in each group

295 The patient's condition was complicated by severe sepsis with positive blood culture Staphylococcus

296 ociated severe sepsis and community-acquired severe sepsis, with higher median length of hospital sta

297 pending on the patients' health prior to the severe sepsis, with the worst affected reporting lasting

298 a strong predictor of disease progression to severe sepsis within 72 hours.

299 efficacy of hydrocortisone in patients with severe sepsis without shock remains controversial.

300 hypothesized that HIV-infected patients with severe sepsis would have worse outcomes compared with th